
HeartBeam (BEAT) Stock Forecast & Price Target
HeartBeam (BEAT) Analyst Ratings
Bulls say
HeartBeam is a medical technology company that has recently developed a proprietary technology platform that allows for 12-lead ECG readings to be taken remotely, rather than solely in a clinical setting. With a growing market for remote and digitally-enabled care models, HeartBeam has the potential to disrupt the $2B mobile cardiac telemetry (MCT) segment with their extended-wear patch, offering capabilities for ischemia detection. However, there are risks to consider such as competition from established monitoring companies and potential capital requirements for commercialization and market expansion. With upcoming milestones including clinical trials for heart attack detection and the limited commercial launch of their technology, HeartBeam seems to be well-positioned for growth.
Bears say
HeartBeam is a medical technology company with a novel ambulatory ECG technology that aims to replicate diagnostic-grade 12-lead ECGs using a compact patient-operated device. Despite its FDA clearance and potential multi-billion-dollar revenue opportunity, the company may face challenges in commercial adoption due to slower physician integration and market development. Additionally, any limitations in technology or product performance could hinder acceptance and ultimately impact the company's competitive positioning.
This aggregate rating is based on analysts' research of HeartBeam and is not a guaranteed prediction by Public.com or investment advice.
HeartBeam (BEAT) Analyst Forecast & Price Prediction
Start investing in HeartBeam (BEAT)
Order type
Buy in
Order amount
Est. shares
0 shares